EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
DH Koo, K Kim, CM Choi, DH Lee, JC Lee… - Cancer chemotherapy …, 2015 - Springer
Purpose Although epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs)
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
have become key therapeutic agents for non-small cell lung cancer (NSCLC) patients with …
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer–A multicenter retrospective SEQUENCE …
GC Chang, CH Tseng, KH Hsu, CJ Yu, CT Yang… - Lung Cancer, 2017 - Elsevier
Background Acquired resistance occurs in most non-small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutations experiencing a response to …
patients with epidermal growth factor receptor (EGFR) mutations experiencing a response to …
[HTML][HTML] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …
Activity of EGFR TKIs in Caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations
A Passaro, A Prelaj, L Bonanno, M Tiseo, A Tuzi… - Clinical lung cancer, 2019 - Elsevier
Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most …
predictive and druggable mutations that greatly modified patient prognoses. The most …
How sensitive are epidermal growth factor receptor tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring epidermal growth factor receptor gene …
A Hata, N Katakami, K Kunimasa… - Journal of Clinical …, 2011 - ascopubs.org
7609 Background: The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitors (TKIs; gefitinib and erlotinib) has been demonstrated in patients with non-small cell …
inhibitors (TKIs; gefitinib and erlotinib) has been demonstrated in patients with non-small cell …
EGFR mutations: Best results from second-and third-generation tyrosine kinase inhibitors
A Manzo, A Montanino, R Costanzo, C Sandomenico… - Oncogenomics, 2019 - Elsevier
In the past few years, the discovery of epidermal growth factor receptor (EGFR) activating
mutations and the demonstration of efficacy of EGFR tyrosine kinase inhibitors (TKIs) have …
mutations and the demonstration of efficacy of EGFR tyrosine kinase inhibitors (TKIs) have …
The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events
Y Sakata, K Kawamura, N Shingu… - Asia‐Pacific Journal …, 2020 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are
used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations …
used to treat patients with non‐small cell lung cancer (NSCLC) and EGFR driver mutations …
[HTML][HTML] Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung …
YW Choi, JH Choi - The Korean Journal of Internal Medicine, 2017 - ncbi.nlm.nih.gov
An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor
receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR …
receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR …
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancers dependent on the epidermal growth factor receptor …
KSH Nguyen, S Kobayashi, DB Costa - Clinical lung cancer, 2009 - Elsevier
Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …
Should every lung cancer patient be tested for EGFR mutation?
F Cappuzzo - Expert opinion on therapeutic targets, 2006 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to
produce dramatic and durable responses in a fraction of non-small cell lung cancer patients …
produce dramatic and durable responses in a fraction of non-small cell lung cancer patients …